To investigate the efficacy and safety of solifenacin combined with biofeedback in the treatment of pediatric neurogenic detrusor overactive (NDO). Twenty children with NDO were involved. The sick children divided into group A and group B. The group A (n=10) was treated with solifenacin. The group B (n=10) was treated with solifenacin combined with biofeedback. The complete response rates, median catheterized volumes, urodynamic parameters and the degrees of vesicouretral reflux (VUR) were compared between the two groups after 4, 8,12 and 24 weeks of the beginning of treatment. After 8 weeks of initial treatment, the complete remission rates of the two groups were 10.0% (1/10) and 20.0% (2/10), respectively. The complete remission rate of the group B was higher than that of the group A (P<0.05). At the 12th weeks after treatment, the complete remission rates in the two groups were 20.0% (2/10) and 40.0% (4/10), respectively. The average urinary catheterization volume of the group B was also increased significantly compared with that before treatment (P<0.05). At the 24th weeks after treatment, the complete remission rates of the two groups were 40.0% (4/10) and 60.0% (6/10), respectively. The improvement of urodynamic parameters such as bladder compliance, detrusor instability and VUR level of children in the group B was better than that of the group A (P<0.05）. During the follow-up period, one child developed constipation. By reducing the dose of solifenacin, the child's constipation was significantly relieved. Solifenacin combined with biofeedback are effective and well tolerated as an available regimen for children with NDO. It is wworthy of widespread clinical adoption.